**2022 coding and reimbursement information**

**HMS Plus and ACT Plus**

---

**Hospital outpatient and physician reimbursement: lab fee schedule**

All Medicare rates displayed in this table reflect the "national unadjusted" amounts inclusive of beneficiary cost-sharing and do not reflect any additional payment adjustments, such as the 2% sequester reduction mandated by the Budget Control Act of 2011 or the 4% PAYGO reduction triggered by the American Rescue Plan in December 2020. Please note that on December 10, 2021, legislation was enacted to delay the 2% sequestration for three months (January 1–March 31, 2022), followed by a reduction of 1% for three months (April 1–June 30, 2022). The full 2% sequestration cut will go back into effect on July 1, 2022. The 4% PAYGO reduction was postponed through January 1, 2023.

<table>
<thead>
<tr>
<th>CPT† code</th>
<th>CPT† code description</th>
<th>Possible LOINC code‡</th>
<th>2022 Medicare lab national unadjusted amount$2</th>
</tr>
</thead>
<tbody>
<tr>
<td>85347</td>
<td>Coagulation time; activated</td>
<td>3184-9</td>
<td>$4</td>
</tr>
<tr>
<td>85520</td>
<td>Heparin assay</td>
<td>81639-7</td>
<td>$13</td>
</tr>
<tr>
<td>85530*</td>
<td>Heparin-protamine tolerance</td>
<td>80893-1</td>
<td>$13</td>
</tr>
</tbody>
</table>

†Recommended for the Heparin Dose Response test with the Medtronic HMS Plus hemostasis management system.
‡Source: http://search.loinc.org. LOINC codes may be required as part of the Medicare Electronic Medical Record Initiative.

**Hospital inpatient reimbursement: MS-drg payment**

- Inpatient billing for labs is typically accomplished through the charge master where the CPT codes above are linked to corresponding lab revenue codes for billing and reimbursed as part of the MS-DRG case rate.
- The MS-DRG payment is dependent upon the primary procedure.

**Reimbursement Disclaimer**

Medtronic does not represent or guarantee that this information is complete, accurate, or applicable to any particular patient or third-party payer. Medtronic disclaims all liability for any consequence resulting from reliance on this document. The final decision of billing for any service must be made by the healthcare provider considering the medical necessity of the service furnished as well as the requirements of third-party payers and any local, state, or federal laws and regulations that apply. Medtronic is providing this information in an educational capacity with the understanding that Medtronic is not engaged in rendering accounting, or other professional services. Medtronic encourages all healthcare providers to consult with their own advisors regarding coding and payment. All Medicare rates displayed in this document reflect the “national unadjusted” amounts inclusive of beneficiary cost-sharing and do not reflect any additional payment adjustments, such as the 2% sequester reduction mandated by the Budget Control Act of 2011 or the 4% PAYGO reduction triggered by the American Rescue Plan in December 2020. Please note that on December 10, 2021, legislation was enacted to delay the 2% sequestration for three months (January 1–March 31, 2022), followed by a reduction of 1% for three months (April 1–June 30, 2022). The full 2% sequestration cut will go back into effect on July 1, 2022. The 4% PAYGO reduction was postponed through January 1, 2023. Medtronic doesn’t offer products with approved indications for all procedures listed. For more information, contact the Cardiovascular Health Economics, Policy & Reimbursement Team.

©2021 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.